Fredun readies CFO appointment amid CARE reporting deviations
Key highlights
- Fredun expects news of a CFO joining within a few months of its November 16, 2026 earnings call.
- Fredun said the CFO candidate has already been with the company for three to four years.
- Fredun has appointed an internal audit team and introduced various audit checks.
- H1 FY27 total income rose 87.02% year on year to Rs 495.88 crore.
powered by IRIS

Fredun Pharmaceuticals Limited said on November 16, 2026, that it expects to announce a CFO appointment within months after an investor raised CARE reporting deviations, and that it has appointed an internal audit team and other audit checks. The response coincides with H1 FY27 total income of Rs 495.88 crore, up 87.02% year on year.
Know Fredun Pharmaceuticals inside out
Results, valuation, peers and who's buying, in one view.
What is Fredun doing about CARE reporting deviations?
Fredun said it is addressing reporting-control concerns through a planned CFO appointment, an internal audit team and “various audit checks.” Managing Director Fredun Medhora outlined these measures on the November 16, 2026, Q2 and H1 FY27 earnings call after an investor asked whether CARE reports issued each quarter warranted a professional CFO.
The investor described the reported deviations as a financial-control concern while Fredun expands. Medhora said CARE had to report the relevant technicalities and that those examining the underlying reasons would understand the issue. The transcript does not identify the individual CARE observations, their monetary value, the affected reporting periods or whether any corrective filing was required.
Fredun also said it was improving day-to-day operations, tightening its numbers and increasing reporting speed. Medhora said investors could see tangible feedback over the next few quarters, but did not quantify a control target or specify a date for completing the new audit processes.
When will Fredun appoint its CFO?
Fredun said news of a CFO joining should come within a few months of the November 16, 2026 call. Medhora said the company was training the CFO candidate and that the person had already been with Fredun for three to four years, indicating an internal succession process rather than a newly disclosed external search.
Fredun did not disclose the candidate’s name, current role, qualifications or formal appointment date. It also did not say whether the appointment would replace an existing finance leader or define responsibility for subsidiaries, which Medhora cited as part of the company’s expanding operations.
Medhora said investors would see “new faces” in addition to the CFO, though no number of planned finance or control hires was disclosed. The measures are management’s stated actions, not confirmation that future CARE observations will end.
How fast did Fredun grow while upgrading controls?
Fredun reported Q2 FY27 total income of Rs 267.64 crore, up 84.21% from Rs 145.29 crore in Q2 FY26. Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 90.74% to Rs 42.6 crore, while net profit increased 93.44% to Rs 18.83 crore.
The H1 FY27 result showed growth across the six-month period rather than only in Q2. Total income reached Rs 495.88 crore, up 87.02% year on year; EBITDA increased 91.67% to Rs 75.38 crore; and net profit rose 93.92% to Rs 31.99 crore.
Fredun’s Q2 FY27 EBITDA margin was 15.92%, up 55 basis points, while net profit margin was 7.03%, up 34 basis points. H1 FY27 EBITDA margin was 15.20%, up 37 basis points, and net profit margin was 6.45%; Q2 EBITDA margin was therefore 72 basis points above the H1 average.
Got a follow-up? Ask IRIS
Which Fredun businesses are growing fastest?
Fredun said its newer businesses are growing faster from smaller bases, with Pet Care rising about 70% to 80%, mobility about 65% to 70%, and mass-market cosmetics about 65% to 70%. Its established or “vintage” business was growing about 15% to 25% year on year from a higher base.
Management linked growth in the established business to registrations and Fredun’s four decades in the industry. It cited Pet Care, mobility, dermaceutics, nutraceuticals, Fredun Gx and supplies to existing export markets as contributors, but gave no revenue, profit or margin figures for any individual line.
Medhora said new-age businesses have intrinsically higher profitability as Fredun shifts from a typical pharmaceutical manufacturing company toward consumer products. He did not provide an EBITDA margin target for FY27 or FY28, saying reporting cycles and business cycles do not always coincide and quarterly margins may change by a couple of points.
Does Fredun still expect to exceed its FY27 revenue target?
Fredun said it expects to do better than its earlier FY27 revenue target of about Rs 800 crore, citing H1 FY27 performance and anticipated traction in the remaining two quarters. This was management’s expectation rather than revised guidance because no replacement FY27 revenue target was announced on the November 16 call.
H1 FY27 income of Rs 495.88 crore represented 61.99% of the earlier Rs 800 crore target. Fredun would need Rs 304.12 crore across the final two quarters to meet that earlier target, although this calculation does not establish the eventual outcome.
For the longer term, Medhora said the company’s “actual growth” could emerge over the next 18 to 24 months, with an inflection point potentially visible in the next few quarters. He did not provide FY29 or FY30 revenue, profit, cash-flow or margin targets.
Conclusion
Fredun’s response to the CARE-related question is a stated governance build-out through an internally trained CFO candidate, an internal audit team and additional audit checks. The timing coincides with H1 FY27 income growth of 87.02% to Rs 495.88 crore and management’s description of newer businesses growing about 65% to 80% from smaller bases.
The next points to watch are the promised CFO announcement within months of November 16, 2026, and the tangible reporting improvements management said could appear over the next few quarters. The final two quarters of FY27 will also test management’s expectation of surpassing its earlier Rs 800 crore revenue target.


